The Technical AnalystExchange: NSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
AstraZeneca Pharma India Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.42% INR5 314.30
America/New_York / 8 mai 2024 @ 05:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 132 858 mill |
| EPS: | 55.54 |
| P/E: | 95.68 |
| Earnings Date: | May 28, 2024 |
| SharesOutstanding: | 25.00 mill |
| Avg Daily Volume: | 0.0223 mill |
| RATING 2024-05-08 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Buy | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 95.68 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 95.68 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
INR2 122.65 (-60.06%) INR-3 191.65 |
| Date: 2024-05-08 |
| Expected Trading Range (DAY) |
|---|
|
INR 5 133.02 - 5 495.58 ( +/- 3.41%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | INR5 314.30 (1.42% ) |
| Volume | 0.0615 mill |
| Avg. Vol. | 0.0223 mill |
| % of Avg. Vol | 275.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ASTRAZEN.NS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ASTRAZEN.NS
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.